Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Cardiol. 2015 Jan 20;179:90-4. doi: 10.1016/j.ijcard.2014.10.032. Epub 2014 Nov 7.

Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion.

Author information

1
University of Giessen, Medizinische Klinik I, Department of Cardiology, Klinikstrasse 33, 35392 Giessen, Germany.
2
University of Giessen, Medizinische Klinik I, Department of Cardiology, Klinikstrasse 33, 35392 Giessen, Germany; Kerckhoff Heart and Thorax Center, Department of Cardiology, Benekestrasse 2-8, 61231 Bad Nauheim, Germany.
3
Kerckhoff Heart and Thorax Center, Department of Cardiology, Benekestrasse 2-8, 61231 Bad Nauheim, Germany.
4
Klinikum Oldenburg, Department of Cardiology, Rahel-Straus-Strasse 10, 26133 Oldenburg, Germany.
5
University of Giessen, Medizinische Klinik I, Department of Cardiology, Klinikstrasse 33, 35392 Giessen, Germany. Electronic address: holger.nef@me.com.

Abstract

OBJECTIVE:

This study evaluates the feasibility of percutaneous coronary intervention with bioresorbable vascular scaffolds (BVSs) in chronic total occlusion (CTO) lesions.

BACKGROUND:

Everolimus-eluting BVSs represent a new approach to treating coronary artery disease, but experience with CTO is limited.

METHODS:

Patients with a previously diagnosed CTO who had been treated with BVS were included. Patients with unsuccessful CTO procedures and patients treated with drug-eluting stents were excluded. Difficulty of the CTO procedure was assessed by the J-score.

RESULTS:

A total of 23 patients were included. Mean age was 60.4 ± 9.0 years, 17.4% were female, 91.3% suffered from hypertension and 34.8% from diabetes. Mean J-score was 1.7 ± 1.0. Median procedure time was 70 min (54-85), mean contrast volume was 213.5 mL (±94.2) and median fluoroscopy time was 19.1 min (13.1-30.0). A total of 64 BVSs were implanted with a mean number of 2.8 ± 1.0 BVSs per patient, a mean total BVS length of 64.8 ± 24.2 mm per lesion, and a mean BVS diameter of 3.1 ± 0.2 mm. Neither a scaffold-related dissection nor any other intra-procedural complication occurred. During a follow-up of 108 (79.5-214.5) days one in-scaffold thrombosis was noted 4 days after the CTO procedure due to a lack of dual antiplatelet therapy. No further major adverse cardiac events occurred.

CONCLUSION:

These results suggest that BVS implantation in CTO lesions can be performed with good procedural success and reasonable clinical short-term outcome in highly selected cases.

KEYWORDS:

Biodegradable; Bioresorbable vascular scaffold; Chronic total coronary occlusion; Coronary artery disease; Percutaneous coronary intervention; Stent

PMID:
25464422
DOI:
10.1016/j.ijcard.2014.10.032
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center